Skip to main content

Table 3 Comparison of the leading two series study of patients in Western and Eastern countries with middle to lower third rectal adenocarcinoma, receiving trans-anal total mesorectal excision assisted by single port laparoscopic surgery

From: Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study

  Meillat et al. The present study P value
Follow-up intervals 1/2012–4/2015 12/2015-12/2018  
Case numbers 41 23  
Age 64 63 N/A
Sex    0.459***
 Male 27 (65.85%) 13 (56.52%)  
 Female 14 (34.15%) 10 (43.48%)  
BMI 24 23 N/A
Neoadjuvant CCRT 30/41 (73.17%) 23/23 (100.00%) 0.005**
Operative time (min) 358 366 N/A
Location of single port    
 Ileostomy site 100% 100% 1.000**
Mobilization of splenic flexure 6/41 (14.63%) 19/23 (82.61%) < 0.001**
Conversion 1/41 (2.44%) 1/23 (4.35%) 0.851*
Complication 10/41 (24.39%) 5/23 (21.74%) 0.815*
Type of anastomosis    < 0.001***
 Hand-sewn 41/41 (100.00%) 14/23 (60.87%)  
 Stapled 0 (0.00%) 9/23 (39.13%)  
Lymph nodes harvested 13 15 N/A
Pathologic T stages    < 0.001***
 ypT0 11 (26.83%) 5 (21.74%)  
 ypT1 4 (9.76%) 5 (21.74%)  
 ypT2 11 (26.83%) 9 (39.13%)  
 ypT3 15 (36.59%) 4 (17.39%)  
Pathologic N stages    < 0.001***
 ypN0 10 (23.39%) 19 (82.61%)  
 ypN1 31 (75.61%) 4 (17.39%)  
Distal margin status    < 0.001*
 R0 38 (92.68%) 23 (100.00)  
 R1 3 (7.32%) 0 (0.00)  
Inter-sphincteric resection 15/41 (36.59%) 14/23 (60.87%) < 0.044**
Length of hospital stays (days) 10 8.4 N/A
  1. N/A not available, BMI body mass index, CCRT concurrent chemoradiotherapy
  2. *Fisher’s exact test
  3. **Student’s t test
  4. ***Chi-squared test